title: [Two cases of pulmonary disease with perinuclear anti-neutrophil cytoplasmic antibody].
abstract: We encountered two cases of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA). The first was a case of idiopathic interstitial pneumonia diagnosed in a 73-year-old man since 1998. He was admitted to our hospital because of renal failure and anemia. The serum level of p-ANCA on admission was 264 EU, and specimens obtained by percutaneous renal biopsy showed crescentic glomerulonephritis and vasculitis due to p-ANCA. He was treated with prednisolone pulse therapy and prednisolone (PSL), however interstitial pneumonia occurred during PSL tapering. We treated him for pulmonary fibrosis with plasmapheresis, methylprednisolone (mPSL) and cyclophosphamide (CPA), which suppressed the progress of the interstitial pneumonia. The second case was one of massive pulmonary hemorrhage in a 68-year-old man who was admitted to our hospital. Physical examination revealed anemia: the laboratory data, renal failure; and the serum level of p-ANCA was elevated to 611 EU. The specimens obtained by percutaneous renal biopsy showed crescentic glomerulonephritis and vasculitis. The renal failure was not improved by PSL, but, together with the inflammation, responded to the combination of PSL and CPA. However, both patients died of serious infection. They were regarded as compromised patients because of the therapy mentioned above. No standard therapy has been established against p-ANCA positive pulmonary disease with renal failure. The treatment should control the progression of interstitial pneumonitis and pulmonary hemorrhage. It is important to consider the possibility of serious infection.
authors.affiliation: First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, 390-8621, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tushima
authors.forename: S
authors.initials: S
authors.lastname: Takashi
authors.forename: H
authors.initials: H
authors.lastname: Gono
authors.forename: A
authors.initials: A
authors.lastname: Tsukadaira
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Kaneki
authors.forename: Y
authors.initials: Y
authors.lastname: Takabayashi
authors.forename: S
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: T
authors.initials: T
authors.lastname: Koizumi
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ohkubo
authors.forename: K
authors.initials: K
authors.lastname: Kubo
mesh_terms: D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D003520:Cyclophosphamide; D011239:Prednisolone